[Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation in Treatment of Intermediate Risk Acute Myeloid Leukemia with Negative for FLT3-ITD, NPM1 or Biallelic CEBPA Mutation].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
; 28(3): 731-736, 2020 Jun.
Article
in Zh
| MEDLINE
| ID: mdl-32552928
ABSTRACT
OBJECTIVE:
To compare the efficacy of haploidentical hematopoietic stem cell transplantation (hi-HSCT) HLA-matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT) and post-remission chemotherapy (PR-CT) in treatment of intermediate risk acute myeloid leukemia with negative for FLT3-ITD, NPM1 or biallelic CEBPA mutation.METHODS:
The clinical data of patients with intermediate risk NPM1wt/non-CEBPAdm/FLT3-ITDneg AML from October 2009 to May 2016 were retrospectively analyzed.RESULTS:
The overall survival rate of the patients treated with PR-CT, MSD-HSCT or hi-HSCT was 63.7%, 71.7%, 75.5%, respectively (Pï¼0.05); the disease-free survival (DFS) rate was 52.8%, 67.1%, 71.3% respectively (Pï¼0.001); the cumulative incidence of relapse was 24.7%, 16.9%, 14.4% respectively (Pï¼0.05); the non-relapse mortality was 26.2%, 17.3%, 14.4% reapectively (Pï¼0.05). The analysis of transplantation, related adverse events showed that II-IV grade of aGVHD in the MSD-HSCT group and hi-HSCT group was 48.9% and 45.6% respectively (Pï¼0.05); the extensive cGVHD event was 21.6% and 8.8% (Pï¼0.05) respectively.CONCLUSION:
The efficiency of hi-HSCT and MSD-HSCT is superior to that of PR-CT for treatment of patients with intermediate risk NPM1wt/non-CEBPAdm/FLT3-ITDneg AML after CR1, there is no statistically significant difference in the efficiency of consolidatorg treatment and the transplantation-related mortality between hi-HSCT and MSD-HSCT.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Myeloid, Acute
/
Hematopoietic Stem Cell Transplantation
Type of study:
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
Zh
Journal:
Zhongguo Shi Yan Xue Ye Xue Za Zhi
Journal subject:
HEMATOLOGIA
Year:
2020
Document type:
Article